Article in Physiological reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors at 1 institution in 1 country.
Michael D WetzelDepartment of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Kristen StanleyDepartment of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Soumya MaityDepartment of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Muniswamy MadeshDepartment of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Jean C BopassaDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Alaa S AwadDepartment of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0002-4468-4446
The University of Texas Health Science Center at San Antonio · US
Funding
PATHOBIOLOGY OF OCCLUSIVE VASCULAR DISEASET32HL007446 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jean Chrisostome Bopassa · 1985 to 2026
$8.9M
Spectral revelations of mitochondrial Ca2+ flux interactomeR01GM109882 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MUNISWAMY, MADESH · 2014 to 2022
$3.3M
Control of Endothelial Mechanotransduction by the Mitochondrial Ca2+ Uniporter: Implications for AtherosclerosisR01HL142673 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI ALEVRIADOU, BARBARA RITA, MUNISWAMY, MADESH · 2018 to 2021
$2.0M
Role of Arginase in Diabetic NephropathyR01DK094930 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI AWAD, ALAA S · 2012 to 2016
$1.9M
Degradation of Mitochondrial Inner Membrane Protein Disrupts the Structural Interaction between Mitofilin and Cyclophilin D and Determines the Extent of Ischemia/reperfusion injuryR01HL138093 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BOPASSA, JEAN CHRISOSTOME · 2017 to 2021
$1.9M
Essential Role for SPG7 in Mitochondrial Permeability Transition Pore Assembly and FunctionR01GM135760 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MUNISWAMY, MADESH · 2020 to 2021
$613k
SIGNAL TRANSDUCTION--HEPATIC SINUSOIDAL XANTHINE OXIDASEF32DK009493 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI BASS, KIRSTEN N · 1996 to 1997
Recently we showed that homoarginine supplementation confers kidney protection in diabetic mouse models. In this study we tested whether the protective effect of homoarginine is nitric oxide synthase-3 (NOS3)-independent in diabetic nephropathy (DN). Experiments were conducted in NOS3 deficient (NOS3
Indexed as
AlbuminuriaAnimalsDiabetes Mellitus, ExperimentalDiabetic NephropathiesHomoarginineKidneyMacrophagesMiceMice, Inbred C57BLMice, KnockoutNitric Oxide Synthase Type IIIOxidative StressStreptozocinHomoarginineNitric Oxide Synthase Type IIINos3 protein, mouseStreptozocincardiac functiondiabetic nephropathyhomoarginineNOS3
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Homoarginine ameliorates diabetic nephropathy independent of nitric oxide synthase-3. · full record | Socratic